Endocyte (ECYT) Removed from Wedbush's Best Ideas List
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq hits near three-month low as Amazon, Intel rattle AI trade
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
- Six killed in cyclone off India's eastern coast
- Amazon (AMZN) Misses Q3 EPS by 7c, Misses on Revenue; Offers Q4 Revenue Guidance
- Sandisk announces 8-for-1 forward stock split effective November 2026
- Reddit, Inc. (RDDT) Tops Q3 EPS by 7c, Beats on Revenue; Offers Q4 Revenue Guidance
- SanDisk stock falls ahead of earnings report
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Baird Downgrades Endocyte (ECYT) to Neutral
May 2, 2014 10:17 AM EDTBaird downgraded Endocyte (NASDAQ: ECYT) from Outperform to Neutral with a price target of $8.00.
For an analyst ratings summary and ratings history on Endocyte click here. For more ratings news on Endocyte click here.
Shares of Endocyte closed at $17.38 yesterday.
... MorePiper Jaffray Downgrades Endocyte (ECYT) to Neutral
May 2, 2014 9:03 AM EDTPiper Jaffray downgraded Endocyte (NASDAQ: ECYT) from Overweight to Neutral with a price target of $13.50.
For an analyst ratings summary and ratings history on Endocyte click here. For more ratings news on Endocyte click here.
Shares of Endocyte closed at $17.38 yesterday.
... MoreEndocyte, Inc. (ECYT) Tops Q1 EPS by 5c; Reports Halt of PROCEED Trial (MRK)
May 2, 2014 8:02 AM EDTEndocyte, Inc. (NASDAQ: ECYT) reported Q1 EPS of ($0.09), $0.05 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $17.3 million versus the consensus estimate of $15.07 million.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and... More
Endocyte, Inc. (ECYT) trading halted with news pending
May 2, 2014 7:57 AM EDTEndocyte, Inc. (NASDAQ: ECYT) trading halted with news pending.
... More


